Implantable Micro-Electrochemical Cell Porous Interface Tissue Irritation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diabetes management systems for glucose sensing and insulin administration are limited in their ability to provide continuous, accurate, and user-friendly monitoring and administration, particularly in terms of implantable sensors and devices that can efficiently measure analytes and deliver medication with minimal user intervention and maximum comfort.
Innovation Solution
An implantable micro-electrochemical cell with a porous interface and cross-linked water-absorbing polymer matrix, integrated with analyte sensors and electrodes, is designed to measure glucose levels and administer insulin, featuring a tubular shape for increased surface area and comfort, and a sealed structure for easy access and reduced tissue irritation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If a traditional glucose sensor is implanted in tissue, then glucose measurement capability is achieved, but tissue irritation and inflammation occur
Solution Approach 1:
A porous polymer membrane is introduced as an intermediary layer between the glucose sensor electrode and the surrounding tissue. This membrane allows glucose molecules to diffuse through to reach the sensor while physically isolating the electrode from direct tissue contact, thereby reducing tissue irritation and inflammation responses
Solution Approach 2:
The patent employs a porous polymer membrane with controlled pore structure that enables selective diffusion of glucose molecules while maintaining physical separation from tissue. The porous structure allows adequate analyte transport to the sensor surface while the membrane material itself acts as a biocompatible barrier reducing foreign body response
2Productivity
If the sensor electrode is directly exposed to tissue, then analyte diffusion is efficient, but foreign body response increases
Solution Approach 1:
The porous polymer membrane is designed with optimized pore size and distribution to ensure adequate glucose diffusion rates while providing effective physical isolation. The porosity is tuned to maintain analyte transport efficiency without compromising the barrier function against tissue reaction
Solution Approach 2:
The sensor structure combines the conductive electrode material with a biocompatible porous polymer membrane, creating a composite structure that integrates both electrical sensing functionality and biological compatibility. This composite approach allows the system to achieve both efficient analyte detection and reduced foreign body response
3Object-affected harmful factors
If the tube is sealed at the open end, then tissue irritation is reduced, but access to internal components becomes difficult
Solution Approach 1:
The sealing structure is designed as a segmented system with a sealed distal end for tissue interface and an accessible proximal end. The electrode lead passes through a feedthrough mechanism that maintains the seal while providing access points, allowing the tube to be sealed where it contacts tissue while remaining open for maintenance and component access at the external end
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This solution enables continuous, accurate glucose monitoring and insulin administration, improving patient comfort and reducing the need for frequent device reimplantation, while maintaining biocompatibility and minimizing tissue irritation.
Implementation Method 1
a fluid medium configured to be in fluid communication with bodily fluid at a tissue site of the patient through at least one porous interface
Implementation Method 2
the porous interface contains a cross-linked water absorbing polymer matrix
Implementation Method 3
an analyte sensor in fluid communication with the fluid medium and configured to measure at least one analyte from the bodily fluid
Data Source
AI summary
A disease management system including an microelectrochemical cell configured to be implanted into a patient. The microelectrochemical cell may include a tube which may include at least one sidewall, a closed end configured to be implanted in the patient, and open end configured to receive a feedthrough for at least one electrode lead. The microelectrochemical cell may further include a fluid medium in fluid communication with bodily fluid, an analyte sensor configured to measure at least one analyte within the bodily fluid, and at least one electrical connection to the analyte sensor at the feedthrough.